Incyte (INCY) Announces Full Phase 3 Results from TRuE-V Program Evaluating Ruxolitinib Cream in Patients With Vitiligo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
October 2, 2021 5:15 AM EDT- Treatment with ruxolitinib cream (Opzelura) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving 75% improvement from baseline in the facial Vitiligo Area Scoring Index
- A significantly greater proportion of patients treated with ruxolitinib cream also achieved 50% improvement from baseline in total body Vitiligo Area Scoring Index (T-VASI50)
- Results will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) 30th Congress
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:... More
